raxibacumab human monoclonal antibody intended prophylaxis treatment inhaled anthrax efficacy proven rabbits december raxibacumab approved united states treatment inhalational anthrax due bacillus anthracis combination appropriate antibacterial drugs prophylaxis inhalational anthrax alternative therapies available antibody discovered joint venture cambridge antibody technology human genome sciences cambridge antibody technology discovered antibody human genome sciencess target hgs purchased glaxosmithkline acquired emergent commonly observed adverse events headaches upper respiratory tract infection nausea pain extremity pruritus skin raxibacumab injection monoclonal antibody targeting protective antigen pa component lethal toxin bacillus raxibacumab developed human genome sciences hgs conjunction us department health human services hhs contract number november meeting antiinfective drugs advisory committee us food drug administration fda members voted support clinical benefit raxibacumab treatment inhalational anthrax one abstention addition committee voted favour riskbenefit profile support fda denied expressed doubt agents added benefit antibiotic levofloxacin levaquin dec fda approved raxibacumab injection treat inhalational anthrax form infectious disease caused breathing spores bacterium bacillus anthracis raxibacumab also approved prevent inhalational anthrax alternative therapies available appropriate antiinfective drug article stub help wikipedia expanding ithttpsenwikipediaorgwikiraxibacumab